Affymetrix to Webcast Presentation at Bank of America Health Care Conference
Posted on: Friday, 1 June 2007, 15:00 CDT
Affymetrix, Inc. (Nasdaq:AFFX) today announced its presentation time at the Bank of America Health Care Conference in Las Vegas has been changed by conference organizers to 11:20 a.m. PT on Friday, June 1, 2007. Doug Farrell, Vice President of Investor Relations, will provide a corporate overview. An archived webcast will be available through Friday, June 15, 2007.
To access the live webcast or archived presentation, find the "Investors" link in the "Resources for" drop-down menu on http://www.affymetrix.com.
About Affymetrix
Affymetrix GeneChip(R) microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,500 systems have been shipped around the world and more than 8,500 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
Source: Business Wire
Related Articles
- Wellcome Trust Case Control Consortium and Affymetrix Expand World's Largest Study of Genetic Diseases
- Affymetrix Applauds Congress and President for Enacting the Genetic Information Nondiscrimination Act
- Marshfield Clinic Research Team Uses Affymetrix DMET Solution to Discover Genetic Variant Affecting Warfarin Metabolism in Patients
- Affymetrix Technology Used to Discover Common Genetic Variant Associated With Height Variation
- Genetic Association Information Network Selects Affymetrix SNP Array 6.0 for Latest Series of Studies
- Affymetrix and CureSearch Children's Oncology Group to Discover and Validate Gene Expression Signatures for Common Childhood Cancers
- Doctors in Pennsylvania Dutch Country Find New Genetic Links to Half Dozen Diseases in Past Year
- Wellcome Trust Case Control Consortium Partners With Perlegen and Affymetrix to Search for Genetic Origins of Ten Complex Diseases
- GlaxoSmithKline to Conduct Whole-Genome Association Studies Using Affymetrix Technology
- Affymetrix Microarrays Uncover Genetic Mutations in Embryonic Stem Cells Approved for Federally-Funded Research; Scientists Report That Majority of Cells Develop Mutations Over Time
 |
 |
User Comments (0)
RSS Feeds